pharmacodynamics

Related by string. pharmacodynamic * * safety tolerability pharmacodynamics . pharmacodynamic parameters . pharmacodynamic effects . pharmacodynamic profile . pharmacokinetic pharmacodynamic . pharmacodynamic properties . pharmacokinetics pharmacodynamics . pharmacodynamic PD . pharmacodynamics PD . pharmacokinetic pharmacodynamic PK PD . pharmacodynamic markers *

Related by context. All words. (Click for frequent words.) 79 pharmacokinetics 77 safety tolerability pharmacokinetics 72 pharmacokinetic 72 pharmacokinetics PK 71 pharmacodynamic profile 71 safety tolerability pharmacokinetic 71 pharmacokinetics pharmacodynamics 70 pharmacokinetic profile 69 pharmacodynamic PD 68 pharmacokinetic profiles 68 active comparator 67 tolerability 67 pharmacokinetic parameters 67 safety tolerability 67 multicenter Phase II 67 pharmacodynamics PD 67 ascending dose 67 tolerability pharmacokinetics 66 ascending doses 66 immunogenicity 66 pharmacodynamic effects 66 pharmacokinetic pharmacodynamic 66 pharmacokinetic characteristics 65 phase IIb clinical 65 anti leukemic 65 pharmacodynamic 65 dose escalation trial 64 Phase Ib clinical 64 analgesic efficacy 64 pharmacokinetic PK 64 preclinical efficacy 64 Phase Ib 64 subcutaneous SC 64 multicenter randomized placebo controlled 64 GRN#L 64 fosbretabulin 64 placebo controlled 63 Blinatumomab 63 pomalidomide 63 subcutaneously administered 63 Phase 1b trial 63 pharmacodynamic properties 63 dose escalation study 63 double blinded placebo 63 teriflunomide 63 HGS ETR2 63 double blinded randomized 63 maximally tolerated dose 63 Phase 1b clinical 63 single ascending dose 63 Azedra 63 viral kinetic 63 pharmacokinetic studies 63 oral prodrug 63 phase IIa clinical 62 pharmacodynamic markers 62 biodistribution 62 glatiramer acetate 62 ritonavir boosted 62 IMC A# 62 pharmacodynamic profiles 62 rHuPH# 62 selective modulator 62 Omacetaxine mepesuccinate 62 oral rivaroxaban 62 dose dose escalation 62 diabetic neuropathic pain 62 dosing regimens 62 CANCIDAS 62 sunitinib malate 62 Phase 2a trial 62 HGS# 62 antiviral efficacy 62 erythropoietic 62 plasma pharmacokinetics 62 PXD# 62 administered subcutaneously 62 Phase Ia 62 CIMZIA TM certolizumab pegol 62 dose escalation 62 preclinically 62 randomized multicenter 62 placebo controlled randomized 62 desvenlafaxine succinate 62 ganetespib 62 oral deforolimus 62 blinded randomized placebo controlled 61 PRTX 61 pharmacokinetic properties 61 Phase IIa trial 61 GAMMAGARD 61 Phase 1a clinical 61 liposomal formulation 61 multicenter Phase III 61 recurrent glioblastoma multiforme 61 dose cohorts 61 polymerase inhibitor 61 dose escalation Phase 61 antitumor activity 61 nucleoside analog 61 Phase 1b 61 tolerability profile 61 APTIVUS 61 Phase #b/#a trial 61 Pharmacokinetics PK 61 fluticasone furoate 61 receptor inhibitor 61 daunorubicin 61 peripheral blood mononuclear 61 pharmacokinetic PK study 61 Cloretazine 61 efficacy tolerability 61 Phase #b/#a 61 randomized Phase III 61 JAK inhibitor 61 systemic RNAi therapeutic 61 mapatumumab 61 Kahalalide F 61 orally bioavailable 61 randomized multicenter trial 61 novel VDA molecule 61 placebo controlled Phase III 61 dose regimens 61 CDK inhibitor 61 Phase Ib II 61 cannabinor 61 Phase 2a clinical 61 vitro cytotoxicity 61 Phase #/#a 61 pharmacokinetic PK profile 61 DermaVir Patch 61 placebo controlled dose escalation 61 phase Ib 61 AEGR 61 teduglutide 61 blind randomized placebo 61 crizotinib PF # 61 intermittent dosing 61 urocortin 2 61 tolerated dose MTD 61 Sym# 61 Phase IIb III 61 blind placebo controlled 61 Carfilzomib 61 Phase Ib clinical trials 61 MGd 60 ZYBRESTAT fosbretabulin 60 galiximab 60 efficacy 60 label dose escalation 60 Phase IIa clinical 60 PSN# [002] 60 antiviral activity 60 ON #.Na 60 placebo controlled Phase 60 dosage regimens 60 RE SURGE 60 ENMD # 60 dose escalation clinical 60 melphalan prednisone 60 davunetide intranasal AL 60 unfractionated heparin UFH 60 Phase Ib study 60 Androxal TM 60 Phase 2b study 60 Omacetaxine 60 indibulin 60 masked placebo controlled 60 thorough QT 60 Phase 2b clinical 60 preclinical pharmacokinetic 60 insulin detemir 60 abacavir lamivudine 60 antithrombotic 60 INCB# [001] 60 nab paclitaxel 60 TAXUS VI 60 dose proportionality 60 prucalopride 60 double blind placebo 60 beta2 agonist 60 retaspimycin 60 PEGylated interferon beta 1a 60 IAP inhibitor 60 relapsing multiple sclerosis 60 pan HDAC inhibitor 60 forodesine 60 DU #b 60 velafermin 60 decitabine 60 depsipeptide 60 multiple ascending dose 60 AEG# 60 Pharmacokinetic 60 controlled multicenter 60 AAG geldanamycin analog 60 Imprime PGG 60 tanespimycin 60 PF # [001] 60 imetelstat 60 Tolvaptan 60 posaconazole 60 nucleotide analog 60 NP2 Enkephalin 60 Aplidin R 60 Elvitegravir 60 placebo controlled clinical 60 busulfan 60 oral diclofenac 60 systemically administered 60 orally administered inhibitor 60 elotuzumab 60 cynomolgus monkeys 60 RE LY trial 60 varespladib 60 demonstrated antitumor activity 60 mg TID 60 ORMD 60 CRLX# 60 DAPT 60 peripherally acting 60 CR# vcMMAE 60 blinded placebo controlled 60 CTCE 60 metaglidasen 60 ISIS # 60 S/GSK# 60 solithromycin 60 multicenter Phase 60 APTIVUS r 59 imatinib resistant 59 Phase 1a 59 safety tolerability pharmacodynamics 59 tolerability profiles 59 Phase IIb clinical 59 ELACYT 59 randomized placebo controlled 59 SCH # 59 clinical pharmacology studies 59 vinca alkaloid 59 vidofludimus 59 antiretroviral naive 59 pharmacodynamic parameters 59 trastuzumab emtansine T DM1 59 coadministration 59 rALLy clinical trial 59 NEUGENE antisense 59 PSMA ADC 59 immunomodulator 59 LUX Lung 59 alvespimycin 59 humanized anti 59 CCX# 59 investigational oral 59 vorinostat 59 fluvastatin 59 interferon gamma 1b 59 phase IIb study 59 placebo controlled clinical trials 59 afatinib 59 mcg dose 59 protease inhibitor PI 59 vicriviroc 59 riociguat 59 NXL# 59 IFN beta 59 viral kinetics 59 intravenously administered 59 2 methoxyestradiol 59 obatoclax 59 Phase IIIb clinical 59 nonclinical studies 59 neratinib 59 orally dosed 59 Afatinib 59 candesartan cilexetil 59 relapsed MM 59 #beta estradiol 59 evaluating tivozanib 59 LEP ETU 59 darunavir ritonavir 59 mecamylamine 59 phase IIb 59 multicenter randomized 59 TMC# C# 59 Amrubicin 59 randomized double 59 CK # administered 59 visilizumab 59 #I TM# 59 gemcitabine Gemzar ® 59 phase 2a 59 CG# [003] 59 PREZISTA r 59 rNAPc2 59 Dual Opioid 59 BAY #-# 59 dose cohort 59 subcutaneous formulation 59 HGS ETR1 59 relapsed multiple myeloma 59 favorable pharmacokinetic profile 59 ALB # 59 pharmacokinetic interactions 59 treatment naive genotype 59 INSPIRE Trial Phase III 59 plasma renin activity 59 PEG SN# 59 edoxaban 59 phase IIa 59 active metabolite 59 Tarceva TM 59 RE LY ® 59 direct thrombin inhibitors 59 Luteinizing Hormone Releasing Hormone 59 randomized clinical 59 pegylated liposomal doxorubicin 59 Symadex 59 sipuleucel T 59 REMINYL ® 59 radiolabeled 59 Navelbine 59 mTOR inhibitors 59 bosentan 59 ToGA 59 EGFR HER2 59 MEND CABG II 59 PRT# 59 cediranib 59 boosted protease inhibitor 59 histone deacetylase inhibitor 59 NATRECOR ® 59 #mg dose [001] 59 pharmacokinetic equivalence 59 genotypic resistance 59 hypoxia activated prodrug 59 blind randomized 59 enzastaurin 59 Dacogen injection 59 OncoVEX GM CSF 59 FOLOTYN ® 59 uricase 59 radezolid 59 CYT# 59 Initiated Phase 58 lenalidomide dexamethasone 58 evaluating REVLIMID 58 LHRH antagonists 58 daily subcutaneous injections 58 plus prednisone 58 erlotinib Tarceva ® 58 multicenter randomized double 58 efavirenz EFV 58 p# biomarkers 58 HCD# [002] 58 HCV NS5B polymerase 58 torezolid phosphate 58 tgAAC# 58 cetuximab Erbitux R 58 dose regimen 58 PEGPH# 58 delafloxacin 58 KRN# 58 CB2 selective receptor agonist 58 CHAMPION PCI 58 eniluracil 58 xenograft models 58 angiotensin receptor blocker ARB 58 Phase IIa 58 DAVANAT 58 synthetic retinoid 58 relapsing remitting multiple sclerosis 58 investigational protease inhibitor 58 RSD# oral 58 Alocrest 58 Triolex 58 chlorambucil 58 elvitegravir 58 novel peptide 58 ACTEMRA TM 58 ALN TTR# 58 mg RDEA# 58 randomized blinded 58 label multicenter 58 insulin lispro 58 Pegasys ® 58 q8h 58 Phase III clinical 58 Pharmacokinetic studies 58 dose limiting toxicities 58 enfuvirtide 58 inhibitor RG# 58 Tamibarotene 58 CBLC# 58 urate lowering 58 ONTARGET 58 pertuzumab 58 GMX# 58 Nanobody 58 ceftazidime 58 antibody MAb 58 Teriflunomide 58 TRV# [001] 58 iodixanol 58 prospective randomized controlled 58 carboplatin paclitaxel 58 CaPre TM 58 Tyrima 58 5 Fluorouracil 58 omega interferon 58 PK PD 58 Triapine R 58 Primary endpoints 58 bendamustine 58 controlled multicenter Phase 58 OMP #M# 58 PEG Interferon lambda 58 lanthanum carbonate 58 PS# [001] 58 serotonin norepinephrine reuptake inhibitor 58 comparator arm 58 octreotide LAR 58 CLORETAZINE TM VNP#M 58 MEK inhibitor 58 oral ridaforolimus 58 Panzem R 58 GRNVAC1 58 atazanavir ritonavir 58 PDE4 inhibitor 58 EZN 58 EURIDIS 58 preclinical studies 58 serum leptin 58 pramlintide metreleptin combination 58 Interferon beta 1a 58 irbesartan 58 TELCYTA 58 estramustine 58 Panzem R NCD 58 immunological responses 58 trastuzumab Herceptin ® 58 TOLAMBA 58 sorafenib Nexavar 58 pramlintide 58 hemostatic efficacy 58 Phase IIb clinical trials 58 multicenter multinational 58 Secondary endpoints 58 pitavastatin 58 gefitinib Iressa 58 CCR5 antagonist 58 LT NS# 58 Bezielle 58 rosuvastatin Crestor 58 gemcitabine cisplatin 58 cilengitide 58 nitazoxanide 58 CYC# 58 orally administered 58 trials RCTs 58 IMA# 58 Phase III randomized 58 antitumoral 58 ISTODAX 58 Interferon alpha 58 GLYX 58 metabolic parameters 58 Enzastaurin 58 dosing schedules 58 μg dose 58 Annamycin 58 axitinib 58 EFAPROXYN 58 allopurinol 58 LEXIVA r 58 Phase IIB 58 Engerix B 58 controlled dose escalation 58 confirmatory clinical 58 zonisamide SR 58 clinical trial 58 PEGylated anti 58 recurrent malignant glioma 58 NOX E# 58 IFN α 58 MAGE A3 ASCI 58 selective inhibition 58 tirofiban 58 gemcitabine carboplatin 58 FOSRENOL ® 58 immune modulating 58 Xanafide 58 dosed orally 58 Chemophase 58 intravenous bolus 58 Betaferon ® 58 long acting muscarinic 58 placebo controlled studies 58 reactogenicity 57 anti Parkinsonian 57 phase IIb trial 57 oral antiviral 57 vapreotide acetate 57 prospective randomized multicenter 57 RELOVAIR ™ 57 latanoprost 57 IIIa inhibitor 57 YONDELIS 57 PHX# 57 somatostatin analog 57 treatment naïve genotype 57 HCV SPRINT 57 optimal dosing 57 Vaxfectin R 57 Iloperidone 57 antitumor effects 57 primary hypercholesterolemia 57 mg dose 57 histone deacetylase HDAC inhibitor 57 ADAGIO study 57 topically administered 57 Phase IIb trial 57 cisplatin gemcitabine 57 Combo Stent 57 NATRECOR R 57 ritonavir boosting 57 Sapacitabine 57 Doxil ® 57 rhIGF-I/rhIGFBP-3 57 relapsed refractory multiple myeloma 57 AVONEX ® 57 Phase III placebo controlled 57 rFVIIa 57 antiangiogenic therapy 57 Androgel R 57 Cmax 57 postmenopausal osteoporotic women 57 PDX pralatrexate 57 oxaliplatin Eloxatin 57 PKC# 57 EMPHASIS HF trial 57 azacitidine 57 rhGH 57 humanised monoclonal antibody 57 NN# [001] 57 Trandolapril 57 Lp PLA 2 57 monotherapy 57 dacarbazine 57 sulodexide 57 R#/MEM # 57 PPAR gamma agonist 57 olmesartan 57 Inhalation Solution 57 XL# SAR# 57 GAMMAGARD LIQUID 57 Neulasta ® 57 Apoptone 57 Antiviral Activity 57 flavopiridol 57 active moiety 57 selective agonist 57 APPRAISE 57 intravesical 57 seliciclib 57 CA4P 57 Traficet EN 57 immunomodulatory therapy 57 TACI Ig 57 Val HeFT 57 antitumor effect 57 Aplidin 57 Aclidinium 57 Epirubicin 57 budesonide foam 57 CIMZIA TM 57 blinded randomized 57 non nucleoside 57 ZACTIMA 57 Randomized controlled 57 LY# [002] 57 HCV RESPOND 2 57 torezolid 57 CYT# potent vascular disrupting 57 pegnivacogin 57 platelet inhibitor 57 MTP inhibitor 57 HIF PH inhibitors 57 hENT1 57 #ME# 57 phase IIb III 57 prasugrel Effient 57 belinostat 57 ZOLINZA 57 RezularTM 57 RG# ITMN 57 eptifibatide 57 Pharmacokinetic parameters 57 phase IIIb 57 Seliciclib 57 mg BID 57 AKT inhibitor 57 VNP#M 57 lintuzumab 57 MNTX 57 Aflibercept 57 CERE 57 sunitinib Sutent ® 57 partial agonist 57 ISENTRESS 57 immunomodulatory 57 radiolabeled TM# 57 mg kg BID 57 Adenoscan R 57 generation purine nucleoside 57 antisense drug 57 Fx #A 57 alemtuzumab Campath 57 Neuradiab 57 plasma concentrations 57 NPH insulin 57 selective antagonist 57 Multimeric 57 idraparinux 57 neutralizing antibody 57 etoposide 57 aripiprazole Abilify 57 REVIVE Diabetes 57 basal bolus regimen 57 Pimavanserin 57 alagebrium 57 multidose 57 NRTI 57 guanfacine 57 thrombopoietin 57 EOquin 57 uric acid lowering 57 paclitaxel Taxol ® 57 randomized Phase 2b 57 Virulizin ® 57 phase Ib clinical 57 vivo 57 HMG CoA reductase inhibitors 57 adalimumab Humira 57 investigational hepatitis C 57 huN# DM1 57 5 HT2C receptor 57 LAB CGRP 57 CLARITY study 57 4mg/kg 57 gemcitabine Gemzar 57 PI3K inhibitor 57 hyperphenylalaninemia HPA due 57 Pharmacokinetic PK 57 prospectively randomized 57 Tarvacin TM 57 Telintra 57 cardiac repolarization 57 IMGN# 57 dextromethorphan quinidine 57 protease inhibitor 57 prospective randomized placebo 57 Onconase 57 hour bronchodilation 57 RDEA# 57 genotypic 57 metreleptin 57 factor G CSF 57 low dose cytarabine 57 APOPTONE 57 antitumor 57 oblimersen 57 multicenter randomized controlled 57 subcutaneous dose 57 factor Xa 57 dose proportional pharmacokinetics 57 TNFalpha 57 CCR5 mAb 57 multicenter phase 57 TELINTRA 57 Degarelix 57 PEG PAL 57 immunomodulatory effects 57 antiretroviral naïve 57 PROCHYMAL 57 ADVANCE PD 57 Thiovir 57 bortezomib Velcade R 57 Debio 57 Neulasta R 57 Maximum Tolerated Dose MTD 57 EXPAREL ™ 57 alfa 2a 57 observer blinded randomized 57 AERAS-#/Crucell Ad# 57 randomized controlled Phase 57 deforolimus 57 JAK2 inhibitors 57 liposomal doxorubicin 57 isoproterenol 57 LEVAQUIN ® 57 metastatic RCC 57 vivo toxicology 57 syngeneic 57 Oral Fingolimod 57 ritonavir boosted atazanavir 57 dose cytarabine 57 BEXXAR Therapeutic Regimen 57 amifostine 57 Phase 2b randomized 57 heavily pretreated 57 kinase inhibition 57 pregabalin Lyrica 57 MEND CABG 57 highly selective inhibitor 57 ARIKACE 57 HCV replicon 57 Belerofon 57 pathophysiological effects 57 intravenous CK # 57 EOquin TM 57 Mg Uk 57 Zenvia ™ 57 factor Xa inhibitor 57 castrate resistant prostate cancer 57 potent antiproliferative 57 protease inhibitors PIs 57 trabectedin 57 thymalfasin 57 CEQ# 57 docetaxel chemotherapy 57 Secondary endpoints include 57 CIMZIA ™ 57 fondaparinux 57 tumor subtypes 56 registrational 56 replicon 56 eltrombopag 56 NS5B polymerase 56 Kinoid 56 biologic DMARD 56 weekly subcutaneous injections 56 intravenous cyclophosphamide 56 synthetic siRNA 56 EDEMA3 56 lintuzumab SGN 56 cefepime 56 MORAb 56 prospectively defined 56 aflibercept VEGF Trap 56 effector function 56 panitumumab Vectibix 56 non nucleoside HCV 56 bortezomib 56 familial amyloidotic polyneuropathy FAP 56 lenalidomide Revlimid R 56 docetaxel Taxotere R 56 clevidipine 56 Elacytarabine 56 mGluR5 NAM 56 Etoposide 56 anticancer agent 56 dosing cohorts 56 LEVADEX 56 avosentan 56 Safinamide 56 MGCD# [001] 56 administered intranasally 56 idarubicin 56 dacetuzumab 56 cytostatic 56 CYP#A# CYP#D# 56 mu opioid receptor antagonist 56 Folfox 56 ALGRX 56 telaprevir dosed 56 ALN HPN 56 tipranavir 56 5 HT2A receptor 56 oral ghrelin agonist 56 IRX 2 56 Peg IFN 56 Oral NKTR 56 Vidaza azacitidine 56 cobicistat 56 novel histone deacetylase 56 IMiDs ® compound 56 ACCOMPLISH 56 evaluating Actimmune 56 pivotal Phase III 56 IFN alpha 56 CERVARIX 56 mycophenolate mofetil 56 isatoribine 56 aplindore 56 Ophena TM 56 antiplatelet agent 56 Annexin V 56 secondary efficacy endpoints 56 vandetanib 56 Factor VIIa 56 pharmacodynamic PK PD 56 azilsartan medoxomil 56 mg QD 56 diarrhea predominant irritable 56 ChronVac C R 56 Fludara 56 #mg/m# [002] 56 prospective observational 56 ataluren 56 K ras mutations 56 goserelin 56 pain palliation 56 virus HCV protease inhibitor 56 nanopharmaceutical 56 MYCAMINE 56 unstable angina UA 56 CD# antibody [001] 56 CRESTOR #mg 56 microdose 56 BENICAR 56 apremilast 56 GFT# 56 fenofibric acid 56 JVRS 56 histamine dihydrochloride 56 trodusquemine 56 fibrotic disease 56 Phase 2b trial 56 caspofungin 56 ESBA# 56 placebo controlled trials 56 stated Michelle Berrey 56 SLx 56 peptide conjugated 56 TO AVOID PREGNANCY WHILE 56 #mg BID [003] 56 Temsirolimus 56 intravenous dosing 56 XmAb# 56 paclitaxel poliglumex 56 docetaxel Taxotere 56 muscarinic 56 Phase III randomized controlled 56 ARRY 56 hMG 56 icatibant 56 XOMA 3AB 56 bleomycin 56 rFIXFc 56 somatostatin 56 Histalean TM 56 multicentre randomized double 56 ancrod 56 docetaxel 56 oral bioavailability 56 intracoronary 56 Archexin 56 adalimumab 56 docetaxel Taxotere ® 56 dosing cohort 56 μg kg 56 antidiabetic 56 investigational humanized monoclonal antibody 56 bicifadine 56 MyVax R 56 HIF 1a 56 nonrandomized 56 budesonide MMX 56 somatostatin analogue 56 mg kg dose 56 randomized multicenter Phase III 56 plasma kallikrein 56 tipranavir r 56 β blockers 56 zileuton 56 prospective multicenter 56 systemic absorption 56 PEG IFN 56 RE LY 56 papillary renal cell carcinoma 56 tolvaptan 56 bioavailability 56 elacytarabine 56 RRMS patients 56 FTY# 56 postprandial glycemia 56 hypoxia inducible factor 56 BRIM3 56 AZX# 56 multicentre randomized 56 Arranon 56 Dapagliflozin 56 mitoxantrone 56 BoNTA 56 ARCOXIA 56 prokinetic agent 56 TDF FTC 56 CINQUIL 56 CK # 56 octreotide 56 intravesical instillation 56 DPP4 56 Enhanze Technology 56 antiplatelet therapies 56 Proellex TM 56 REG1 56 dasatinib Sprycel 56 OvaRex ® MAb 56 Spheramine 56 JAK2 inhibitor 56 chain antibody fragment 56 refractory CLL 56 factorial design 56 Phase 1b clinical trials 56 Fulvestrant 56 liposome injection 56 pivotal Phase 56 omecamtiv mecarbil 56 PegIFN 56 huC# DM4 56 anti angiogenic agents 56 targeting CD# 56 latrepirdine 56 HIV integrase inhibitor 56 GLP toxicology studies 56 Pharmacokinetics 56 subcutaneous doses 56 HORIZONS AMI trial 56 glucose lowering 56 investigational drug 56 TPI ASM8 56 vitro experiments 56 Voreloxin 56 BRIM2 56 TRANSFORMS 56 celgosivir 56 lispro 56 bolus dose 56 QT QTc 56 multicenter clinical 56 beta interferons 56 cytoprotective 56 HCV protease 56 continuous intravenous infusion 56 ATACAND 56 PRADAXA 56 CTAP# Capsules 56 fosamprenavir 56 topoisomerase II inhibitor 56 fostamatinib 56 IMiDs R 56 paclitaxel eluting stents 56 dexamethasone Decadron 56 imatinib therapy 56 Vidofludimus 56 5 FU leucovorin 56 PD LID 56 SAR# [004] 56 AQ4N 56 noninferiority 56 oral JAK1 56 Pivotal Phase III 56 Pemetrexed 56 VKORC1 56 CCR2 56 Natalizumab 56 bevirimat 56 nelfinavir 56 mcg BID 56 tumorigenicity 56 bronchodilatory 56 HBeAg negative patients 56 cMET 56 FASLODEX 56 mRNA expression 56 PROSTVAC VF 56 LEXIVA 56 SCIg 56 RG# [001] 56 immune modulator 56 Raltegravir 56 INTERCEPT platelets 56 retapamulin 56 selectively inhibits 56 rifalazil 56 HIV HCV coinfected 56 anti fibrotic 56 plus dexamethasone 56 fallopian tube cancers 56 Akt activation 56 dasatinib Sprycel ® 56 MEK inhibitors 56 Anticalins ® 56 pegylated interferon alfa 2a 56 Dasatinib 56 amprenavir 56 pharmacodynamic endpoints 56 ribavirin RBV

Back to home page